Generic Name and Formulations:
Valsartan 40mg+, 80mg, 160mg, 320mg; +scored; tabs.
Company:
Novartis Pharmaceuticals Corp
Indications for DIOVAN:
Heart failure (NYHA Class II–IV). To reduce cardiovascular mortality in stable post-MI patients with left ventricular failure or dysfunction.
Adult Dose for DIOVAN:
Heart failure: initially 40mg twice daily, increase to 80mg twice daily, then to 160mg twice daily as tolerated. Post-MI: may start 12hrs post-MI; initially 20mg twice daily, increase within 1 wk to 40mg twice daily; target maintenance: 160mg twice daily as tolerated. Low BP or renal dysfunction: reduce dose.
Children's Dose for DIOVAN:
Not recommended.
Pharmacological Class:
Angiotensin II receptor blocker.
Contraindications:
Concomitant aliskiren in diabetics.
Warnings/Precautions:
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before beginning therapy (may need to reduce diuretic) or monitor closely for hypotension. Hepatic or renal impairment (monitor). Renal artery stenosis. Severe CHF (if renal function depends on renin-angiotensin-aldosterone system). Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
Interactions:
Concomitant K+ supplements, K+ sparing diuretics, K+ containing salt substitutes may lead to hyperkalemia and, in heart failure patients, increased serum creatinine. May be antagonized by, and renal toxicity potentiated by, NSAIDs, including selective COX-2 inhibitors (monitor renal function periodically in elderly and/or volume depleted). May be potentiated by inhibitors of OATP1B1 (eg, rifampin, cyclosporine) or MPR2 (eg, ritonavir). Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended.
Adverse Reactions:
Dizziness, hypotension, diarrhea, arthralgia, back pain, fatigue, hyperkalemia, increased BUN, neutropenia, rhabdomyolysis (rare).
Metabolism:
Hepatic (CYP2C9); 95% protein bound.
Elimination:
Fecal, renal.
Generic Availability:
NO
How Supplied:
Tabs 40mg—30; 80mg, 160mg, 320mg—90
部份中文Diovan处方资料（仅供参考）
缬沙坦是血管紧张素受体拮抗剂，可用于各种类型高血压，并对心脑肾有较好的保护作用。心肌梗塞、心力衰竭、蛋白尿、糖尿病等高血压病人可做为常规使用，可与利尿剂（如氢氯噻嗪）联合使用。
药理作用
缬沙坦是一种口服有效的特异性的血管紧张素Ⅱ（AT1）受体提起拮抗剂，它选择性地作用于AT1受体亚型，阻断AngⅡ与AT1受体的结合（其特异性拮抗AT1受体的作用大于AT2受体约20,000倍），从而抑制血管收缩和醛固酮的释放，产生降压作用。该品不作用于血管紧张素转换酶（ACE）、肾素和其它受体，不抑制与血压和钠平衡有关的离子通道；该品对血管紧张素转换酶没有抑制作用，不影响体内缓激肽水平，因而导致咳嗽的副作用少于血管紧张素转换酶抑制剂。 缬沙坦降低升高的血压，同时不影响心律。 对大多数患者，单剂口服2小时内产生降压效果，4-6小时达作用高峰，降压效果维持至服药后24小时以上，治疗2-4周后达最大降压疗效，并在长期治疗期间保持疗效。与噻嗪类利尿剂合用可进一步增强降压效果。 突然终止缬沙坦治疗，不引起高血压“反跳”或其他副作用。 缬沙坦不影响高血压患者的总胆固醇、甘油三酯、血糖和尿酸水平。
适应症
抗高血压、轻中度原发性高血压，尤其适用肾脏损害所致继发性高血压。
用法用量
Diovan的推荐剂量为80mg，每日一次，与种族、年龄或性别无关。抗高血压作用通常在服药2周内出现，4周时达到最大疗效。对血压控制不满意的病人，每日用量可增至160mg，或加用利尿剂。对肾功能不全患者或无胆管源性及胆汁瘀积型肝功能不全患者无需调节剂量。Diovan可与其它抗高血压药合用。